SillaJen's 'Pexavac' Conducts Phase 1b and 2 Clinical Trials for Melanoma in China

SillaJen 'Pexavac' (Photo by SillaJen)

[Asia Economy Reporter Chunhee Lee] SillaJen announced on the 23rd that it has started patient dosing in China for the Phase 1b/2 clinical trial of combination therapy using the anticancer drug candidate 'Pexa-Vec' and the immune checkpoint inhibitor 'Socazolimab' from its Chinese partner Liscam for the treatment of melanoma.

This clinical trial targets 46 patients with advanced or metastatic melanoma who have failed first-line treatment. The Phase 1b trial will continue until the second quarter of next year, after which it will transition to Phase 2 following safety evaluation.

In Phase 1b, patients will be divided into low-dose and high-dose groups for Pexa-Vec and Socazolimab to determine the dosage for Phase 2. The trial is conducted in an open-label manner, where both patients and researchers are aware of the administered doses.

Socazolimab is an immune checkpoint inhibitor officially approved in China this year. Liscam imported it from Sorento, a U.S.-based new drug development company.

This content was produced with the assistance of AI translation services.